Patent · US Active

Thienopyrazoles

US7518000B2 · kind B2 · utility

1Cited by

2References

12Claims

0Family size

Assignee

Aventis Pharmaceuticals Inc. · US

Inventors

John Gerald Jurcak · Bethlehem, US
Matthieu Barrague · New Brunswick, US
Timothy Alan Gillespy · Fryeburg, US
Michael Edwards · Suffolk, US
Kwon Yon Musick · Raritan, US
Phillip Marvin Weintraub · Hackettstown, US
Yan Du · Bound Brook, US
Ramalinga M. Dharanipragada · Montgomery, US
Ashfaq Ahmed Parkar · Piscataway, US

Key dates

Filing date	Mar 6, 2006
Grant date	Apr 14, 2009
Priority date	—
Expiry date	Sep 29, 2026

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Thienopyrazoles of formula I, their preparation, pharmaceutical compositions comprising these compounds, and their pharmaceutical uses in the treatment of disease states capable of being modulated by the inhibition of the protein kinases, in particular interleukin-2 inducible tyrosine kinase (ITK).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.